ArticleAnnals of surgical oncology2026
Neoadjuvant Dual-Targeted HER2 Therapy and Neoadjuvant Chemo-Immunotherapy is Associated with Improved Nodal pCR and Reduced Axillary Surgery.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic therapy advances such as dual-agent human epidermal growth factor receptor 2 (HER2)-targeted therapy (addition of pertuzumab in 2013) and immunotherapy (IO) for triple-negative breast cancer (TNBC) (introduction of pembrolizumab in 2021) improved pathologic complete response (pCR) and overall survival (OS). This study assessed impact on nodal pCR (npCR) rate and its association with axillary lymph node dissection (ALND) trends and OS.
methodsUsing the National Cancer Database, this study identified patients from 2010 to 2023 who had cN+ stage II or III HER2+ or TNBC treated with neoadjuvant chemotherapy. The study evaluated patients who had TNBC treated without IO (2010-2020) and with IO (2021-2023) and patients who had HER2+ disease treated in 2010-2013 (single-agent HER2-targeting era) and 2014-2023 (dual-agent era), respectively. Chi-square tests and multivariable Cox proportional hazards regression compared percentages and analyzed OS.
resultsThe study identified 49,186 HER2+ and 36,612 TNBC patients. Rates of npCR improved in all subtypes. The npCR rates were higher among patients who had TNBC treated with IO (69%) than among those who had who had TNBC treated without IO (52%; p < 0.001). In HER2+ disease, npCR was higher in the dual-agent era than in the single-agent era (57% vs 48% for estrogen receptor-positive [ER+]/HER2+ and 77% vs 61% for estrogen receptor-negative [ER-]/HER2+ [each p < 0.001]). In TNBC with IO, ALND decreased from 67 to 50% overall, from 50 to 38% in ypN0, and from 83 to 77% in ypN+. In HER2+ disease, the ALND rate similarly decreased in the dual-agent era overall, in ypN0, and in ypN+. With respect to OS, TNBC with nodal pCR alone had better OS than with breast pCR alone (hazard ratio [HR], 0.77; p < 0.001).
conclusionsThe dual-targeting era for HER2 disease and the use of IO for TNBC are associated with increased nodal pCR. Nodal pCR is associated with decreased ALND.
Indexed as
Identifiers
42766268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.